Drug development company Avexa Ltd
(ASX:AVX) has appointed Dr Jonathan Coates as interim CEO.
Drug inventor Dr Coates will also resume his previous role of chief scientific officer.
Dr Coates has more than 25 years experience in antiviral drug discovery and will head the Melbourne based company whilst it investigates commercial options and conducts an independent review of its programs.
The company says Dr Coates is an experienced candidate to lead the company, as it conducts an independent review and continues discussion with regulatory authorities in relation to its HIV drug candidate, Apricitabine.
Avexa reported a loss of $36.22 million for the year ending 30 June 2009.
